Sonoma Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting revenues of $7,174 thousand for the three months ended September 30, 2026, alongside a net loss of $66 thousand for the same period.

Key Highlights

  • Quarterly revenue of $7,174 thousand for the three months ended September 30, 2026, up from $5,604 thousand in the same period a year earlier, according to the filing.
  • Net loss narrowed to $66 thousand for the three months ended September 30, 2026, compared to a net loss of $534 thousand in the three months ended September 30, 2025.
  • Six-month revenue reached $13,580 thousand for the period ended September 30, 2026, versus $9,619 thousand in the comparable prior-year period.
  • Cash and cash equivalents increased to $4,609 thousand at September 30, 2026, from $2,399 thousand at March 31, 2026, with net proceeds from common stock issuances of $3,848 thousand cited as a financing source.
  • Total stockholders' equity grew to $6,614 thousand at September 30, 2026, from $3,095 thousand at March 31, 2026, the filing disclosed.
  • Shares outstanding were 5,057,755 at September 30, 2026, up from 1,799,057 at March 31, 2026, reflecting At-the-Market and direct common stock issuances during the period.
  • Accumulated deficit stood at $201,377 thousand as of September 30, 2026, compared to $200,981 thousand at March 31, 2026.

Sonoma Pharmaceuticals' Financial Results for the Quarter Ended September 30, 2026

According to the filing, Sonoma Pharmaceuticals (NASDAQ:SNOA) reported revenues of $7,174 thousand for the three months ended September 30, 2026, an increase from $5,604 thousand in the three months ended September 30, 2025. Cost of revenues for the same quarterly period was $4,367 thousand, yielding a gross profit of $2,807 thousand, compared to a gross profit of $2,120 thousand in the prior-year quarter. Total operating expenses for the quarter were $2,517 thousand, resulting in income from operations of $290 thousand, versus a loss from operations of $337 thousand a year earlier.

For the six months ended September 30, 2026, the company reported revenues of $13,580 thousand and a net loss of $396 thousand, or $0.09 per basic and diluted share, compared to revenues of $9,619 thousand and a net loss of $1,775 thousand, or $1.08 per basic and diluted share, in the six months ended September 30, 2025, the filing stated. The weighted-average number of shares outstanding on a basic and diluted basis for the six-month period was 4,381 thousand, versus 1,643 thousand in the prior-year comparable period.

On the balance sheet, total assets were $17,103 thousand at September 30, 2026, compared to $13,960 thousand at March 31, 2026, the filing disclosed. The company's cash position increased to $4,609 thousand, supported in part by $3,848 thousand in net proceeds from the issuance of common stock, including At-the-Market and direct offerings. Net cash used in operating activities was $1,385 thousand for the six months ended September 30, 2026, an improvement from $2,650 thousand used in the comparable prior-year period. A withholding tax payable of $5,692 thousand remained on the balance sheet as of September 30, 2026.

What Was Disclosed

Sonoma Pharmaceuticals filed a 10-Q for the quarterly period ended September 30, 2026, disclosing revenue growth, a narrowed net loss, higher cash balances, and a significant increase in shares outstanding due to stock issuances during the first half of fiscal year 2027.